Executive Summary
Burcon NutraScience Corporation, together with its subsidiary, develops plant proteins and ingredients for use in the food and beverage industries in Canada.
Snowflake
Fundamentals
Flawless balance sheet with high growth potential.
Share Price & News
How has Burcon NutraScience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-18.3%
BU
-1.5%
CA Chemicals
-0.3%
CA Market
1 Year Return
216.9%
BU
-11.2%
CA Chemicals
4.8%
CA Market
Return vs Industry: BU exceeded the Canadian Chemicals industry which returned -11.2% over the past year.
Return vs Market: BU exceeded the Canadian Market which returned 4.8% over the past year.
Shareholder returns
| BU | Industry | Market | |
|---|---|---|---|
| 7 Day | -18.3% | -1.5% | -0.3% |
| 30 Day | -39.8% | -3.7% | -3.3% |
| 90 Day | 0% | -6.2% | -1.6% |
| 1 Year | 216.9%216.9% | -8.1%-11.2% | 8.5%4.8% |
| 3 Year | -66.5%-66.5% | -6.9%-12.4% | 14.8%4.5% |
| 5 Year | -56.9%-56.9% | -21.2%-29.5% | 26.6%8.1% |
Price Volatility Vs. Market
How volatile is Burcon NutraScience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
What does Burcon Nutrascience Corporation's (TSE:BU) Balance Sheet Tell Us About Its Future?1 year ago | Simply Wall St
Who Owns Burcon Nutrascience Corporation (TSE:BU)?1 year ago | Simply Wall St
Should You Worry About Burcon Nutrascience Corporation's (TSE:BU) CEO Salary Level?Valuation
Is Burcon NutraScience undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BU (CA$1.03) is trading below our estimate of fair value (CA$16.76)
Significantly Below Fair Value: BU is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BU is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.
PE vs Market: BU is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BU is overvalued based on its PB Ratio (7.5x) compared to the CA Chemicals industry average (1.2x).
Next Steps
Future Growth
How is Burcon NutraScience forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
63.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BU is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: BU is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BU's is expected to become profitable in the next 3 years.
Revenue vs Market: BU's revenue (65.9% per year) is forecast to grow faster than the Canadian market (5.6% per year).
High Growth Revenue: BU's revenue (65.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BU's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Burcon NutraScience performed over the past 5 years?
5.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: BU is unprofitable, but has reduced losses over the past 5 years at a rate of 5.5% per year.
Accelerating Growth: Unable to compare BU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BU is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-25.7%).
Return on Equity
High ROE: BU has a negative Return on Equity (-41.41%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: BU is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: BU is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Burcon NutraScience's financial position?
Financial Position Analysis
Short Term Liabilities: BU's short term assets (CA$7.4M) exceeds its short term liabilities (CA$756.7K)
Long Term Liabilities: BU has no long term liabilities
Debt to Equity History and Analysis
Debt Level: BU is debt free.
Reducing Debt: BU had no debt 5 years ago.
Balance Sheet
Inventory Level: BU has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if BU's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BU has sufficient cash runway for 1.794311 years if free cash flow continues to grow at historical rates of 5.1% each year.
Next Steps
Dividend
What is Burcon NutraScience's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate BU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if BU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BU's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
What is the CEO of Burcon NutraScience's salary, the management and board of directors tenure and is there insider trading?
10.1yrs
Average management tenure
CEO
Johann Tergesen (56yo)
0.8yrs
Tenure
CA$285,746
Compensation
Mr. Johann Franz Tergesen, MBA, CPA, CA, serves as the President of Burcon NutraScience Corporation (formerly Burcon Capital Corp.) since September 2000 and serves as the Chief Executive Officer since Janu ...
CEO Compensation Analysis
Compensation vs. Market: Johann has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Canadian market.
Compensation vs Earnings: Johann's compensation has been consistent with company performance over the past year.
Management Age and Tenure
10.1yrs
Average Tenure
Experienced Management: BU's management team is seasoned and experienced (10.1 years average tenure).
Board Age and Tenure
3.8yrs
Average Tenure
76yo
Average Age
Experienced Board: BU's board of directors are considered experienced (3.8 years average tenure).
Insider Trading
Insider Buying: BU insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chairman of the Board Chairman & Lead Director |
| Shares | 70,055 |
| Max Price | CA$1.59 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 100,000 |
| Max Price | CA$1.25 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 100,000 |
| Max Price | CA$1.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 50,000 |
| Max Price | CA$0.80 |
| Entity | Individual |
| Role | Chief Executive Officer President & CEO |
| Shares | 56,000 |
| Max Price | CA$0.67 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 50,000 |
| Max Price | CA$0.62 |
| Entity | Individual |
| Role | Chief Executive Officer President & CEO |
| Shares | 125,000 |
| Max Price | CA$0.59 |
| Entity | Individual |
| Role | Chairman of the Board Chairman & Lead Director |
| Shares | 21,556 |
| Max Price | CA$1.91 |
| Entity | Company |
| Shares | 1,566,719 |
| Max Price | CA$0.20 |
| Entity | Individual |
| Shares | 1,566,719 |
| Max Price | CA$0.20 |
| Entity | Individual |
| Role | Chief Executive Officer President & CEO |
| Shares | 20,000 |
| Max Price | CA$0.16 |
| Entity | Individual |
| Role | Chief Executive Officer President & CEO |
| Shares | 50,000 |
| Max Price | CA$0.15 |
| Entity | Individual |
| Role | Chief Executive Officer President & CEO |
| Shares | 120,000 |
| Max Price | CA$0.17 |
| Entity | Individual |
| Role | Chief Executive Officer President & CEO |
| Shares | 70,000 |
| Max Price | CA$0.23 |
Ownership Breakdown
Management Team
Johann Tergesen (56yo)
President & CEO
- Tenure: 0.8yrs
- Compensation: CA$285.75k
Dorothy Law (50yo)
Senior VP of Legal & Corporate Secretary
- Tenure: 10.1yrs
- Compensation: CA$145.37k
Randy Willardsen
Senior Vice President of Process
- Tenure: 17.9yrs
- Compensation: CA$142.09k
Jade Cheng
CFO & Treasurer
- Tenure: 0yrs
- Compensation: CA$185.79k
Martin Schweizer
Vice President of Technical Development
- Tenure: 10.1yrs
- Compensation: CA$182.73k
Board Members
Paul Westdal
Director Emeritus
- Tenure: 0yrs
- Compensation: CA$48.72k
Rosanna Chau (64yo)
Director
- Tenure: 20.9yrs
- Compensation: CA$19.22k
Doug Gilpin (80yo)
Independent Director
- Tenure: 8.1yrs
- Compensation: CA$25.22k
David Lorne Tyrrell (76yo)
Chairman & Lead Director
- Tenure: 0.8yrs
- Compensation: CA$23.72k
Alan Chan
Director
- Tenure: 9.5yrs
- Compensation: CA$18.47k
Peter Kappel
Independent Director
- Tenure: 3.8yrs
- Compensation: CA$13.34k
David Ju
Independent Director
- Tenure: 1.8yrs
- Compensation: CA$20.06k
Calvin Ng
Director
- Tenure: 0.3yrs
Company Information
Burcon NutraScience Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Burcon NutraScience Corporation
- Ticker: BU
- Exchange: TSX
- Founded: 1998
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: CA$90.842m
- Shares outstanding: 88.20m
- Website: https://www.burcon.ca
Number of Employees
Location
- Burcon NutraScience Corporation
- 1946 West Broadway
- Vancouver
- British Columbia
- V6J 1Z2
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BU | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Feb 1999 |
| BNE | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Feb 1999 |
| BURO.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Feb 1999 |
Biography
Burcon NutraScience Corporation, together with its subsidiary, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company’s products include CLARISOY, a soy ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/23 23:33 |
| End of Day Share Price | 2019/10/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.